Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
Humanigen, Inc. (NASDAQ: HGEN) announced that CEO Cameron Durrant will present at the H.C. Wainwright Global Investment Conference on May 23-26, 2022, in Miami, FL, at 11:00 am EDT. The presentation will update on the topline data release for ACTIV-5/BET-B and the company's plans for 2022. With over 1 million COVID-19 hospitalizations and 173,738 deaths in the U.S. this year, Humanigen emphasizes the need for additional therapeutics. A webcast of the event will be available on Humanigen's investor relations website for 90 days.
- CEO's presentation at a significant investment conference can boost visibility.
- Focus on updating topline data for ACTIV-5/BET-B, indicating progress in clinical trials.
- Continued high hospitalization and death rates from COVID-19 highlight ongoing public health challenges.
- Uncertainties surrounding the development and regulatory approval of new therapeutics remain.
“There have been 1 million hospitalizations and 173,738 deaths with COVID-19 to date this year, placing the
A livestream will be available and a webcast link to a recording of the event will be posted to the “Events and Presentations” section of Humanigen’s investor relations website for 90 days after the event at ir.humanigen.com.
Webcast: https://journey.ct.events/view/8e10da2e-d387-4ab0-97c2-fd6aec9fd7ef
About
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our plans relating to lenzilumab.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.
References
-
Centers for Disease Control and Prevention . (2022,May 23 ).CDC Covid Data tracker.Centers for Disease Control and Prevention . RetrievedMay 23, 2022 , from https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions -
Centers for Disease Control and Prevention . (2022,May 23 ).CDC Covid Data tracker.Centers for Disease Control and Prevention . RetrievedMay 23, 2022 , from https://covid.cdc.gov/covid-data-tracker/#trends_totaldeaths
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005429/en/
Humanigen Investor Relations
trbo@humanigen.com
650-410-3206
Source:
FAQ
What will Cameron Durrant discuss at the H.C. Wainwright Global Investment Conference?
When is Humanigen's presentation at the investment conference?
What is the focus of Humanigen's clinical development?
How many COVID-19 hospitalizations have occurred in the U.S. this year?